Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer

NCT04503694 is registered in ClinicalTrials.gov with Jules Bordet Institute as lead sponsor.

NCT NCT04503694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04503694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer
Lead sponsor
Jules Bordet Institute
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 25, 2021
Completion date
December 31, 2032
Enrollment
72 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer stage ii, rectal cancer stage iii